SCHEMBL276182

SCHEMBL276182

COC(=O)c1ccc(C(=O)NN2CCOCC2)s1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.66
CYP2D6 P10635 1/20 0.51
KMT2A Q03164 3/20 0.48
MAPK1 P28482 2/20 0.48
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HPGD P15428 2/20 0.46
ALDH1A1 P00352 3/20 0.43
ALOX15 P16050 1/20 0.43
MGLL Q99685 1/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
LIPE Q05469 1/20 0.42
NPSR1 Q6W5P4 2/20 0.42
RECQL P46063 1/20 0.42
PPARG P37231 1/20 0.42
NCOA2 Q15596 1/20 0.42
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5269934 0.85 MAPK1 (0.50) HTTKMT2AMAPK1LMNAHPGD
SCHEMBL277132 0.84 KMT2A (0.68) HTTCYP2D6KMT2AMAPK1LMNA
SCHEMBL279600 0.82 HTT (0.69) HTTCYP2D6KMT2AMAPK1LMNA
SCHEMBL276922 0.82 HTT (0.69) HTTCYP2D6KMT2AMAPK1LMNA
SCHEMBL12313815 0.80 HTT (0.66) HTTCYP2D6KMT2AMAPK1LMNA
SCHEMBL1588349 0.79 HPGD (0.76) KMT2AHPGDALDH1A1ALOX15MGLL
SCHEMBL12265883 0.79 HTT (0.64) HTTCYP2D6KMT2AMAPK1LMNA
SCHEMBL277405 0.79 KMT2A (0.61) KMT2ALMNAALDH1A1ALOX15MEN1
SCHEMBL14395480 0.78 HTT (0.68) HTTCYP2D6KMT2AMAPK1LMNA
SCHEMBL3823243 0.75 HRH3 (0.60) KMT2AMAPK1LMNASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL HTT 1630/4885CYP2D6 2749/4885KMT2A 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.